Proliferation, hyperplasia, neogenesis, and neoplasia in the islets of Langerhans

Pancreas

Volumn 35, Issue 3, 2007, Pages 199-206

  Ballian, Nikiforos ^a   Hu, Min ^b   Liu, Shi He ^b   Brunicardi, F Charles ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Islets of Langerhans; Pancreas; Pancreatic neoplasia; Somatostatin

Indexed keywords

GROWTH FACTOR; PANCREAS HORMONE;

APOPTOSIS; CELL DIVISION; CELL FUNCTION; CELL PROLIFERATION; CELL STRUCTURE; HUMAN; INNER CELL MASS; PANCREAS DISEASE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL; PANCREAS ISLET CELL HYPERPLASIA; PANCREAS TUMOR; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ANIMALS; CELL DIVISION; CRICETINAE; FEEDBACK, BIOCHEMICAL; GLUCOSE; HORMONES; HUMANS; HYPERPLASIA; HYPERTROPHY; INSULINOMA; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISLETS OF LANGERHANS; MICE; MICE, TRANSGENIC; ORGAN SIZE; PANCREATIC NEOPLASMS; PLURIPOTENT STEM CELLS; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 34748858026     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e318074c6ed     Document Type: Review

References (100)

1. Hennig R, Ding XZ, Adrian TE. On the role of the islets of Langerhans in pancreatic cancer. Histol Histopathol. 2004;19:999-1011.
2. American Diabetes Association, 2005. National diabetes fact sheet [National Diabetes Association Web site]. Available at: http://www.diabetes.org/ uedocuments/NationalDiabetesFactSheetRev.pdf. Accessed March 3, 2007.
3. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
4. Pour PM, Pandey KK, Batra SK. What is the origin of pancreatic adenocarcinoma? Mol Cancer. 2003;2:13.
5. Schmied BM, Ulrich AB, Friess H, et al. The patterns of extrainsular endocrine cells in pancreatic cancer. Teratog Carcinog Mutagen. 2001;21:69-81.
6. Grube D, Bohn R. The microanatomy of human islets of Langerhans, with special reference to somatostatin (D-) cells. Arch Histol Jpn. 1983;46:327-353.
7. Bonner-Weir S. Islet growth and development in the adult. J Mol Endocrinol. 2000;24:297-302.
8. Duvillie B, Currie C, Chrones T, et al. Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to beta-cell hyperplasia in mutant mice lacking insulin. Endocrinology. 2002;143:1530-1537.
9. Bernal-Mizrachi E, Wen W, Stahlhut S, et al. Islet beta-cell expression of constitutively active Akt1/PKBalpha induces striking hypertrophy, hyperplasia and hyperinsulinemia. J Clin Invest. 2001;108:1631-1638.
10. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.
11. Georgia S, Bhushan A. Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. J Clin Invest. 2004;114:963-968.
12. Del Zotto H, Borelli MI, Flores L, et al. Islet neogenesis: an apparent key component of long-term pancreas adaptation to increased insulin demand. J Endocrinol Invest. 2004;183:321-330.
13. Zhang YQ, Sarvetnick N. Development of cell markers for the identification and expansion of islet progenitor cells. Diabetes Metab Res Rev. 2003;19:363-374.
14. Swenne I. Pancreatic beta-cell growth and diabetes mellitus. Diabetologia. 1992;35:193-201.
15. Guz Y, Nasir I, Teitelman G. Regeneration of pancreatic beta cells from intra-islet precursor cells in an experimental model of diabetes. Endocrinology. 2001;142:4956-4968.
16. Zulewski H, Abraham EJ, Gerlach MJ, et al. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes. 2001;50:521-533.
17. Gagliardino JJ, Del Zotto H, Massa L, et al. The pancreatic duodenal homeobox-1 (Pdx-1)/islet neogenesis-associated protein (INGAP): a possible combined marker of activateable islet-cell precursors. J Endocrinol. 2003;177:249-259.
18. Finegood DT, Scaglia L, Bonner-Weir S. Dynamics of beta-cell mass in the growing rat pancreas. Estimation with a simple mathematical model. Diabetes. 1995;44:249-256.
19. Tyrberg B, Eizirik DL, Hellerstrom C, et al. Human pancreatic beta-cell deoxyribonucleic acid-synthesis in islet grafts decreases with increasing organ donor age but increases in response to glucose stimulation in vitro. Endocrinology. 1996;137:5694-5699.
20. Dor Y, Brown J, Martinez OI, et al. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature. 2004;429:41-46.
21. Lai Y, Schneider D, Kidszun A, et al. Vascular endothelial growth factor increases functional beta-cell mass by improvement of angiogenesis of isolated human and murine pancreatic islets. Transplantation. 2005;79:1530-1536.
22. Laybutt DR, Glandt M, Xu G, et al. Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. J Biol Chem. 2003;78:2997-3005.
23. Steil GM, Trivedi N, Jonas JC, et al. Adaptation of beta-cell mass to substrate oversupply: enhanced function with normal gene expression. Am J Physiol Endocrinol Metab. 2001;280:E788-E796.
24. Weir GC, Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004;53:S16-S21.
25. Kassem SA, Ariel I, Thornton PS, et al. Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes. 2004;49:1325-1333.
26. Lorenzo A, Razzaboni B, Weir GC, et al. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature. 1994;368:756-760.
27. Scaglia L, Smith FE, Bonner-Weir S. Apoptosis contributes to the involution of beta cell mass in the post partum rat pancreas. Endocrinology. 1995;136:5461-5468.
28. Jamal AM, Lipsett M, Sladek R, et al. Morphogenetic plasticity of adult human pancreatic islets of Langerhans. Cell Death Differ. 2005;12:702-712.
29. Butler AE, Janson J, Soeller WC, et al. Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes. 2003;52:2304-2314.
30. Bernard C, Berthault MF, Saulnier C, et al. Neogenesis vs. apoptosis as main components of pancreatic beta cell ass changes in glucose-infused normal and mildly diabetic adult rats. FASEB J. 1999;13:1195-1205.
31. Bernard C, Thibault C, Berthault MF, et al. Pancreatic beta-cell regeneration after 48-h glucose infusion in mildly diabetic rats is not correlated with functional improvement. Diabetes. 1998;47:1058-1065.
32. Bonner-Weir S, Deery D, Leahy JL, et al. Compensatory growth of pancreatic beta-cells in adult rats after short-term glucose infusion. Diabetes. 1989;38:49-53.
33. Paris M, Bernard-Kargar C, Berthault MF, et al. Specific and combined effects of insulin and glucose on functional pancreatic beta-cell mass in vivo in adult rats. Endocrinology. 2003;144:717-2727.
34. Swenne I. The role of glucose in the in vitro regulation of cell cycle kinetics and proliferation of fetal pancreatic beta-cells. Diabetes. 1982;31:754-760.
35. Hagman DK, Hays LB, Parazzoli SD, et al. Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans. J Biol Chem. 2005;280:32413-32418.
36. Deng S, Vatamaniuk M, Huang X, et al. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes. 2004;53:624-632.
37. Leahy JL. Impaired beta-cell function with chronic hyperglycemia: 'overworked beta-cell' hypothesis. Diabetes Rev. 1996;4:298-319.
38. Maedler K, Spinas GA, Lehmann R, et al. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes. 2001;50:1683-1690.
39. Frodin M, Sekine N, Roche E, et al. Glucose, other secretagogues, and nerve growth factor stimulate mitogen-activated protein kinase in the insulin-secreting beta-cell line, INS-1. J Biol Chem. 1995;270:7882-7889.
40. Hugl SR, White MF, Rhodes CJ. Insulin-like growth factor I (IGF-I)-stimulated pancreatic beta-cell growth is glucose-dependent. Synergistic activation of insulin receptor substrate-mediated signal transduction pathways by glucose and IGF-I in INS-1 cells. J Biol Chem. 1998;273:17771-17779.
41. Khoo S, Cobb MH. Activation of mitogen-activating protein kinase by glucose is not required for insulin secretion. Proc Natl Acad Sci U S A. 1997;94:5599-5604.
42. Andersson A. The influence of hyperglycaemia, hyperinsulinaemia and genetic background on the fate of intrasplenically implanted mouse islets. Diabetologia. 1983;25:269-273.
43. Guillen C, Navarro P, Robledo M, et al. Differential mitogenic signaling in insulin receptor-deficient fetal pancreatic beta cells. Endocrinology. 2006;147:1959-1968.
44. Koiter TR, Wijkstra S, Schaaf-Verdonk CJD, et al. Pancreatic beta-cell function and islet-cell proliferation: effect of hyperinsulinaemia. Physiol Behav. 1995;57:717-721.
45. Blume N, Skouv J, Larsson LI, et al. Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis. J Clin Invest. 1995;96:2227-2235.
46. Flatt PR, Tan KS, Bailey CJ, et al. Effects of transplantation and resection of a radiation-induced rat insulinoma on glucose homeostasis and the endocrine pancreas. Br J Cancer. 1986;54:685-692.
47. Miyaura C, Chen L, Appel M, et al. Expression of reg/PSP, a pancreatic exocrine gene: relationship to changes in islet beta-cell mass. Mol Endocrinol. 1991;5:226-234.
48. Pelengaris S, Khan M. Oncogenic co-operation in beta-cell tumorigenesis. Endocr Relat Cancer. 2001;8:307-314.
49. Laybutt DR, Weir GC, Kaneto H, et al. Overexpression of c-Myc in beta-cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes. Diabetes. 2002;51:1793-1804.
50. Laybutt DR, Kaneto H, Hasenkamp W, et al. Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to beta cell survival during chronic hyperglycemia. Diabetes. 2002;51:413-423.
51. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002;109:321-334.
52. Schuhmacher M, Staege MS, Pajic A, et al. Control of cell growth by c-Myc in the absence of cell division. Curr Biol. 1999;9:1255-1258.
53. Jetton TL, Lausier J, LaRock K, et al. Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase. Diabetes. 2005;54:2294-2304.
54. Tuttle RL, Gill NS, Pugh W, et al. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. Nat Med. 2001;7:1133-1137.
55. Ashizawa S, Brunicardi FC, Wang XP. PDX-1 and the pancreas. Pancreas. 2004;28:109-120.
56. Johnson JD, Ahmed NT, Luciani DS, et al. Increased islet apoptosis in Pdx1+/- mice. J Clin Invest. 2003;111:1147-1160.
57. Kulkarni RN, Jhala US, Winnay JN, et al. PDX-1 haploinsufficiency limits the compensatory islet hyperplasia that occurs in response to insulin resistance. J Clin Invest. 2004;114:828-836.
58. Sharma A, Zangen DH, Reitz P, et al. The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration. Diabetes. 1999;48:507-513.
59. O'Reilly LA, Gu D, Sarvetnick N, et al. Alpha-cell neogenesis in an animal model of IDDM. Diabetes. 1997;46:559-606.
60. Kumar U, Sasi R, Suresh S, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes. 1999;48:77-85.
61. Portela-Gomes GM, Stridsberg M, Grimelius L, et al. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol. 2000;8:126-132.
62. Strowski MZ, Parmar RM, Blake AD, et al. Somatostatin inhibits insulin and glucagon secretion via two receptor subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. Endocrinology. 2000;141:111-117.
63. Strowski MZ, Kohler M, Chen HY, et al. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol Endocrinol. 2003;17:93-106.
64. Wang XP, Yang J, Norman MA, et al. SSTR5 ablation in islet results in alterations in glucose homeostasis in mice. FEBS Lett. 2005;579:3107-3114.
65. Wang XP, Norman MA, Yang J, et al. Double gene ablation of SSTR1 and 5 results in hyperinsulinemia and improved glucose tolerance in mice. Surgery. 2004;136:585-592.
66. Zambre Y, Ling Z, Chen MC, et al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharmacol. 1999;57:1159-1164.
67. Buscail L, Delesque N, Esteve J, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. 1994;91:2315-2319.
68. Cordelier P, Esteve JP, Bousquet C, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci U S A. 1997;94:9343-9348.
69. Lahlou M, Guillermet J, Hortala M, et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci. 2004;1014:121-131.
70. Lamberts SWJ, Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab. 2002;13:451-457.
71. Schally AV. Oncological applications of somatostatin analogues. Cancer Res. 1988;48:6977-6985.
72. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol. 1996;10:1688-1696.
73. Wang XP, Norman MA, Yang J, et al. The effect of global SSTR5 gene ablation on the endocrine pancreas and glucose regulation in aging mice. J Surg Res. 2005;129:64-72.
74. Wang XP, Norman M, Yang J, et al. Alterations in glucose homeostasis in SSTR1 gene-ablated mice. Mol Cell Endocrinol. 2006;247:82-90.
75. Lazarus SS, Folk BW. The effect of protracted glucagon administration on blood glucose and pancreatic morphology. Endocrinology. 1958;63:359-371.
76. Gelling RW, Du XQ, Dichmann DS, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A. 2003;100:1438-1443.
77. Vincent M, Guz Y, Rozenberg M, et al. Abrogation of protein convertase 2 activity results in delayed islet cell differentiation and maturation, increased alpha-cell proliferation, and islet neogenesis. Endocrinology. 2003;144:4061-4069.
78. Dombrowski F, Klingmuller D, Pfeifer U. Insulinomas derived from hyperplastic intra-hepatic islet transplants. Am J Pathol. 1998;152:1025-1038.
79. Bertolino P, Tong WM, Galendo D, et al. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol. 2003;17:1880-1892.
80. Biondi CA, Gartside MG, Waring P, et al. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol Cell Biol. 2004;24:3125-3131.
81. Dilley WG, Kalyanaraman S, Verma S. Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome. Mol Cancer. 2005;4:9.
82. Folkman J, Watson K, Ingber D, et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58-61.
83. Gannon G, Mandriota SJ, Cui L, et al. Overexpression of vascular endothelial growth factor-A165 enhances tumor angiogenesis but not metastasis during beta-cell carcinogenesis. Cancer Res. 2002;62:603-608.
84. Gocheva V, Zeng W, Ke D, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006;20:543-556.
85. Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004;5:443-453.
86. Schmied B, Liu G, Moyer MP, et al. Induction of adenocarcinoma from hamster pancreatic islet cells treated with N-nitrosobis(2-oxopropyl) amine in vitro. Carcinogenesis. 1999;20:317-324.
87. Pour PM, Kazakoff K. Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Am J Pathol. 1996;149:1017-1025.
88. Pour PM, Kazakoff K, Carlson K. Inhibition of streptozotocin-induced islet cell tumors and N-nitrosobis(2-oxopropyl)amine-induced pancreatic exocrine tumors in Syrian hamsters by exogenous insulin. Cancer Res. 1990;50:1634-1639.
89. Bell RHJ, Pour PM. Pancreatic carcinogenicity of N-nitrosobis(2- oxopropyl)-amine in diabetic and non-diabetic Chinese hamsters. Cancer Lett. 1987;34:221-230.
90. Schneider MB, Matsuzaki H, Haorah J, et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology. 2001;120:1263-1270.
91. Meckler KA, Brentnall TA, Haggitt RC, et al. Familial fibrocystic pancreatic atrophy with endocrine cell hyperplasia and pancreatic carcinoma. Am J Surg Pathol. 2001;25:1047-1053.
92. Garcia-Ocaña A, Takane KK, Syed MA, et al. Hepatocyte growth factor overexpression in the islet of transgenic mice increases beta cell proliferation, enhances islet mass, and induces mild hypoglycemia. J Biol Chem. 2000;275:1226-1232.
93. Sorenson RL, Brelje TC. Adaptation of islets of Langerhans to pregnancy: beta-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res. 1997;29:301-307.
94. Vasavada RC, Garcia-Ocaña A, Zawalich WS, et al. Targeted expression of placental lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation, and hypoglycemia. J Biol Chem. 2000;275:15399-15406.
95. Porter SE, Sorenson RL, Dann P, et al. Progressive pancreatic islet hyperplasia in the islet-targeted, parathyroid hormone-related protein-overexpressing mouse. Endocrinology. 1998;139:3743-3751.
96. Devedjian JC, George M, Casellas A, et al. Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes. J Clin Invest. 2000;105:731-740.
97. Okamoto H. The Reg gene family and Reg proteins: with special attention to the regeneration of pancreatic beta-cells. J Hepatobiliary Pancreat Surg. 1999;6:254-262.
98. Bouwens L, Rooman I. Regulation of pancreatic beta-cell mass. Physiol Rev. 2005;85:1255-1270.
99. Kojima H, Fujimiya M, Matsumura K, et al. NeuroD-betacellulin gene therapy induces islet neogenesis in the liver and reverses diabetes in mice. Nat Med. 2003;9:596-603.
100. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol. 2003;17:161-171.